Michael Lim

TL;DR: It is shown that PTEN messenger RNA can be reintroduced into PTEN-null prostate cancer cells in vitro and in vivo via its encapsulation in polymer–lipid hybrid nanoparticles coated with a polyethylene glycol shell and this work provides proof-of-principle evidence of the restoration of mRNA-based tumour suppression in vivo.

TL;DR: Various nanodelivery systems that improve DNA vaccine technologies to enhance the immunological response against target diseases are discussed.

TL;DR: The potential of biomaterials engineering as well as various natural and synthetic delivery technologies to overcome the challenges of M cell targeting, all of which are absent in current literature are presented.

TL;DR: The authors wish to add the following sentence into the ‘Competing interests’ section of this Article: “P.W.K. has investment interest in Context Therapeutic LLC, DRGT, Placon, Seer Biosciences and Tarveda Therapeutics.”

TL;DR: In this article , the authors summarized the current clinical trials underway by evaluating the leading immunotherapy paradigms, the encountered barriers, and the future directions needed to overcome such tumor evasion.